retatrutide glp-1 gip glucagon triple agonist Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data retatrutide triple agonist glp-1 gip

In addition to its neuroprotective properties, GIP has been shown to influence the regulation of food consumption and body weight through mechanisms operating within the central nervous system (CNS)

GIP receptors are highly expressed in pancreatic beta cells and adipose tissue, but are present at minimal or negligible levels in the liver and skeletal muscle, suggesting tissue-specific mechanisms

These drugs were also found to cause weight loss and have been subsequently used to treat obesity

Often, they switch to fertility-supportive treatments like metformin while continuing to address other PCOS symptoms

You can read a more in-depth explanation and analysis of risk from the Cleveland Clinic , but heres the bottom line: Out of an abundance of caution, anyone with a personal or family history making them more susceptible to C cell thyroid cancer (specifically) is advised not to use a GLP-1 medication

At TrimRx, our mission is to simplify this process, providing a telehealth-first approach that merges clinical expertise with the convenience of modern technology